How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Intramedullary distraction for lower limb lengthening

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Draft recommendations

    2.1 Evidence on the safety and efficacy of intramedullary distraction for lower limb lengthening is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    2.2 Clinicians wishing to do intramedullary distraction for lower limb lengthening should:

    • Inform the clinical governance leads in their healthcare organisation.

    • Give patients (and their families and carers as appropriate) clear information to support shared decision making, including NICE's information for the public.

    • Ensure that patients (and their families and carers as appropriate) understand the procedure's safety and efficacy, and any uncertainties about these.

    • Audit and review clinical outcomes of all patients having the procedure. The main efficacy and safety outcomes identified in this guidance can be entered into NICE's interventional procedure outcomes audit tool (for use at local discretion).

    • Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve.

    2.3 Healthcare organisations should:

    • Ensure systems are in place that support clinicians to collect and report data on outcomes and safety for every patient having this procedure.

    • Regularly review data on outcomes and safety for this procedure.

    2.4 This technically challenging procedure should only be done in specialist centres by surgeons with training and specific experience in limb lengthening techniques.

    2.5 Report any problems with a medical device using the Medicines and Healthcare products Regulatory Agency's Yellow Card Scheme.

    2.6 Further research should report details of patient selection, device selection, procedural outcomes, long-term outcomes including quality of life, the need for repeat interventions or surgery, and complication rates.